**Core tip:** Both hepatic arterial infusion chemotherapy (HAIC) and sorafenib plus transcatheter arterial chemoembolization (TACE) combination therapy are widely used as a treatment of choice in patients with hepatocellular carcinoma (HCC) in Asia. However, the safety and efficacy of sorafenib combined with HAIC (folinic acid, 5-fluorouracil, and oxaliplatin) after TACE for intermediate and advanced HCC have not been firmly established. In the present study, we confirmed the efficacy and safety of this combination therapy. We believe that this study can help doctors and patients to select appropriate therapy.

INTRODUCTION
============

Hepatocellular carcinoma (HCC) is the sixth most common malignancy and the fourth leading cause of cancer-related death worldwide\[[@B1]\]. However, 70%-80% of patients with HCC are diagnosed at an advanced stage and are ineligible for curative therapies\[[@B2]\]. New locoregional modalities, including radiofrequency ablation (RFA) and arterially directed therapy, can improve the prognosis of patients with HCC\[[@B3]\]. The Asia-Pacific clinical practice guidelines\[[@B4]\] on the management of HCC recommend transcatheter arterial chemoembolization (TACE) as a first-line treatment for HCC in patients with unresectable, large/multifocal HCCs who do not have vascular invasion or extrahepatic spread. TACE is associated with a longer overall survival (OS) than systemic chemotherapy and is associated with fewer adverse events (AEs)\[[@B5]-[@B7]\]. However, TACE has unclear effects on patients with large HCCs (tumor diameter greater than 10 cm) and those with vascular invasion \[portal vein tumor thrombosis (PVTT) and vascular infiltration\]. In previous studies\[[@B8]-[@B11]\], hepatic arterial infusion chemotherapy (HAIC) is a recommended treatment for advanced HCC with portal vein invasion and for large HCC. HAIC can directly deliver chemotherapeutic drugs to the tumor-supplying artery to increase drug concentration and reduce the toxicity of systemic chemotherapy. HAIC is recommended for HCC in Japan and China\[[@B12],[@B13]\], and in Western countries, some studies\[[@B14],[@B15]\] have reported the safety and efficacy of HAIC for HCC. Oxaliplatin and 5-fluorouracil (5-FU) infused *via* the hepatic artery have been proven to be safe in phase I clinical studies and pharmacokinetic analyses\[[@B16],[@B17]\].

Recent studies focusing on TACE in combination with other interventional therapies for HCC have shown that treatments such as RFA, microwave ablation, sorafenib, and HAIC are safe and effective and show promising outcomes\[[@B18]-[@B22]\]. A prospective phase II trial\[[@B21]\] revealed that TACE combined with HAIC was superior to TACE alone for inoperable HCC. The objective response rate (ORR) in the TACE-HAIC treatment group was higher than that in the TACE-only group (68.9% *vs* 45.9%), and the median progression-free survival (mPFS) in the TACE-HAIC group was significantly better than that in the TACE-only group (8.0 mo *vs* 4.5 mo) among patients with inoperable HCC.

Sorafenib is the most widely used systemic therapy approved as a first-line agent for unresectable or advanced HCC\[[@B23]\]. In two randomized, double-blind phase III trials\[[@B24],[@B25]\], sorafenib was effective and well tolerated for the treatment of advanced HCC. Sorafenib can inhibit tumor revascularization and reduce the recurrence and metastasis of tumors\[[@B26]-[@B29]\]. The efficacy of sorafenib combined with TACE is conflicting in some trials (SPACE, TACE-2, and TACTICS). However, the TACTICS and OPTIMIS trials found that sorafenib combined with TACE benefited PFS (TACTICS) and OS (OPTIMIS), respectively, and the timing of sorafenib was crucial in these studies. The TACTICS trial was well-designed for evaluating the timing of sorafenib and creating a new definition of disease progression\[[@B29]-[@B31]\]. In the START trial\[[@B32],[@B33]\], sorafenib in combination with TACE, especially the combination that improved the OS of early-intermediate-stage HCC, was found to be a safe and effective therapy for patients with advanced-stage HCC.

In previous studies, sorafenib exerted a synergistic anticancer effect with chemotherapeutic agents\[[@B34]\]. Some studies\[[@B35],[@B36]\] have shown that sorafenib combined with HAIC \[folinic acid, 5-FU, and oxaliplatin (FOLFOX)\] can effectively reduce the tumor burden of HCC with portal vein invasion. In a randomized, multicenter phase III trial\[[@B36]\], the median OS of the group treated with sorafenib plus HAIC (FOLFOX) was longer than that of the HAIC-only group (13.37 mo *vs* 7.13 mo). In addition, the sorafenib group showed a higher response rate (51% *vs* 3%) and had a longer median PFS (7.03 mo *vs* 2.6 mo) than the HAIC-only group.

As TACE is the most widely used treatment for intermediate and advanced HCC, sorafenib combined with TACE is considered a safe and effective therapy for patients with advanced-stage HCC, and sorafenib combined with HAIC is recommended for HCC with portal vein invasion. However, few reports have examined the effect of sorafenib combined with TACE-HAIC for intermediate and advanced HCC. Thus, we evaluated the safety and efficacy of a combined therapeutic strategy with sorafenib and TACE-HAIC in patients with advanced HCC.

MATERIALS AND METHODS
=====================

Participant eligibility
-----------------------

All participants were diagnosed by pathology or the American Association for the Study of Liver Disease criteria\[[@B37]\]. All participants satisfied the following criteria: (1) Age 18-75 years; (2) Eastern Cooperative Oncology Group performance status 0-2; (3) Child-Pugh class A or B7; (4) Intermediate and advanced HCC (including patients with extrahepatic metastasis and portal vein invasion); (5) White blood cell count \> 3 × 10^9^/L and neutrophil count \> 1.5 × 10^9^/L; (6) Serum creatinine \< 2 mg/dL and albumin level \> 3.0 mg/dL; and (7) Left ventricular ejection fraction \> 45%. The exclusion criteria were as follows: (1) Other malignancies; (2) Uncontrollable infections (\> grade 2 infections; infections that required antibiotic or surgical interventions or were life-threatening; (3) Pregnancy or breastfeeding; (4) Previous sorafenib treatment; and (5) Severe allergies to contrast agents or other drugs.

Study design
------------

All participants received sorafenib and underwent TACE-HAIC (FOLFOX). Patients were treated on a 4- to 6-wk cycle regimen, in which one cycle consisted of sorafenib 400 mg twice daily, and then TACE-HAIC was performed on days 1-2. Sorafenib was continued with TACE-HAIC intervention. Sorafenib and TACE-HAIC were continued until progressive disease (PD) (If there was a new tumor node \> 5 mm, this was considered the first instance of PD, and treatment was continued until PD was identified twice. Then, the patient was excluded from the study. The PFS was recorded from the first instance of PD), intolerable toxicity, or death. The tumor response was evaluated after every two cycles of treatment and every 3 mo during maintenance treatment \[contrast-enhanced magnetic resonance imaging (MRI) or computed tomography (CT)\]. The tumor response was evaluated by the modified Response Evaluation Criteria for Solid Tumors (mRECIST). We tried to keep the imaging examination (CT or MRI) consistent before and after treatment to increase accuracy, and two experienced radiologists with 11 and 12 years of experience in abdominal imaging determined the tumor responses by consensus. The criteria for terminating treatment and the TACE-HAIC scheme are shown in Figure [1](#F1){ref-type="fig"}.

![Scheme of transcatheter arterial chemoembolization-hepatic arterial infusion chemotherapy and sorafenib. TACE: Transcatheter arterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy; 5-FU: 5-fluorouracil; PVA: Polyvinyl alcohol; CF: Calcium folinate; EPI: Epirubicin; OXA: Oxaliplatin.](WJGO-12-663-g001){#F1}

Procedures
----------

**TACE technique:** The Seldinger technique was used to access the femoral artery after injection of local anesthesia. Arteriography was performed to gather information regarding the abdominal aorta, celiac trunk, and portal venous system before chemoembolization treatments for all participants. A 2.7-F microcatheter (Renegade Hi Flo, Boston Scientific, United States; Stride ASAHI INTECC, Japan) was coaxially advanced through an external catheter to select the tumor arteries. Subsequently, lipiodol (total volume \< 20 mL; lipiodol, Laboratoire Andre Guerbet, Aulnaysous-Bois, France) mixed with 20-40 mg of emulsified epirubicin (Main Luck Pharmaceutical, Shenzhen, China) was injected to embolize the tumor arteries; for some large tumors, 100-300 µm/300-500 µm embospheres (Biosphere Medical, Rockland, MA, United States) were used for embolization. Chemoembolization was performed first if there were extrahepatic parasitic blood arteries. In patients with an arterioportal shunt, embolization with 350-1000 μm of gelatin sponge particles was performed to occlude the shunt *via* super-selective catheterization before infusion of lipiodol. A temporary indwelling catheter was inserted into the feeding artery of the tumor until the end of HAIC. If there were bilobar HCC tumors with a low tumor burden, conventional TACE (cTACE) was performed for both tumors, and the tip of catheter was inserted into the proper hepatic artery or common hepatic artery. If there were bilobar HCC tumors with a high tumor burden, embolization of tumor was performed in steps to reduce the risk of hepatic failure. The position of the catheter was determined according to the tumor location.

**HAIC technique:** A microcatheter was externally connected to an arterial infusion pump (Model LP 2000-P2) in the ward, and oxaliplatin \[60-75 mg/m^2^ (Child-Pugh A, 75 mg/m^2^ and Child-Pugh B, 60 mg/m^2^)\] was administered intra-arterially for 6 h; leucovorin 200 mg/m^2^ was intravenously administered for 2 h (the peripheral vein for 2 h at the beginning of the 5-FU infusion), and 5-FU \[1.0-1.5 g/m^2^ (Child-Pugh A, 1.5 g/m^2^ and Child-Pugh B, 1 g/m^2^)\] was intra-arterially administered for 18 h). At the end of the procedure, we extracted the arterial catheter and put pressure on the puncture point for 24 h. TACE-HAIC was performed every 4-6 wk. A maximum of eight consecutive cycles of HAIC were used for patients without disease progression during the treatments. All doctors had more than 10 years of experience in interventional oncology.

**Sorafenib:** Before the treatment, sorafenib (200 mg) was administered orally twice daily; 400 mg was administered orally twice daily if the drug tolerance was acceptable. The dose of sorafenib was reduced (600 mg or 400 mg orally per day) based on treatment-related toxicities. Treatment was discontinued because of disease progression, unacceptable toxicity, or treatment refusal.

Assessments
-----------

All participants had their complete medical histories taken, and abdominal contrast-enhanced CT or MRI and chest X-ray and/or CT were performed during the baseline physical examination. Enhanced CT or MRI were performed after each cycle of therapy, and laboratory tests \[blood examinations, biochemical tests, coagulation testing, and measurement of serum alpha-fetoprotein (AFP) levels\] were performed before each cycle of therapy; AEs were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE) v4.03. Participants were followed until death or until they were lost to follow-up. Tumor response was defined as complete response (CR), partial response (PR), or stable disease (SD). Tumor control was defined as a CR, PR, or SD (evaluated using mRECIST). It should be noted that CR was defined as a tumor disappearing on contrast-enhanced CT and/or MRI combined with a normalized AFP level. All tumors (liver tumors, lymph node metastases, or metastatic tumors) were evaluated using mRECIST.

If the patients demonstrated stable conditions with a CR, sorafenib was continued, and TACE-HAIC treatment was stopped. AFP levels were reevaluated every 3 mo, and contrast-enhanced MRI or CT evaluations were conducted. Once liver tumors were classified as PD, sorafenib and TACE-HAIC were stopped, and patients underwent other therapy or were followed for survival. When a participant suffered an intolerable toxicity, treatment was suspended, and the drug dose was adjusted. If the patient still could not tolerate treatment, the treatment was discontinued.

Statistical analysis
--------------------

The primary endpoints were safety and PFS. PFS was defined as the time from the date of the first TACE-HAIC treatment until disease progression. The null hypothesis of a 12-mo PFS rate of approximately 30% was based on the results of a clinical trial recently completed in our department with the same TACE-HAIC regimen\[[@B21]\]. This hypothesis was tested against the alternative hypothesis of a true rate of 50% or higher. To evaluate this hypothesis with 90% power and an alpha level of 0.05, which is considered indicative of a statistically significant difference, 60 patients had to be included. Considering a drop-out rate of 10%, a total of 66 patients were recruited.

The secondary endpoints were the ORR and OS. Response was evaluated using the mRECIST, and AEs were evaluated using the CTCAE v4.03. OS and PFS were estimated using the Kaplan-Meier method. Hazard ratios and their 95% confidence intervals (CIs) were calculated. All analyses were performed with SPSS version 22.0 (IBM Corp., Armonk, NY, United States). A *P* value \< 0.05 was considered statistically significant.

RESULTS
=======

Participant characteristics
---------------------------

From February 2012 to December 2016, 66 participants were enrolled in this prospective study (Figure [2](#F2){ref-type="fig"}). The mean age in this study was 53.3 ± 11.7 years. Most participants were male (39/66, 83.3%), and cirrhosis was present in 75.8% of participants (50/66). The mean tumor size in this study was 6.7 cm ± 4.3 cm. In the present study, 56.1% (37/66) of participants had Barcelona Clinic Liver Cancer (BCLC) stage C disease, and 43.9% (29/66) had BCLC stage B disease. A total of 81.8% (54/66) of the participants had hepatitis B virus infection. The characteristics and demographics of the 66 consecutive participants are presented in Table [1](#T1){ref-type="table"}.

###### 

Baseline characteristics

  **Parameter**                 **Number of participants (*n* = 66)**
  ----------------------------- ---------------------------------------
  Mean age (yr)                 53.3 ± 13.6
  Sex                           
  Male                          55
  Female                        11
  Maximum tumor diameter (cm)   
  ≤ 5                           27
  5-10                          26
  \> 10                         13
  Child-Pugh score              
  A                             57
  B7                            9
  BCLC stage                    
  B                             29
  C                             37
  ECOG PS                       
  0                             46
  1                             20
  Vascular invasion             
  Present                       25
  Absent                        41
  Portal vein invasion          
  Present                       23
  Absent                        43
  Extrahepatic metastasis       
  Present                       16
  Absent                        50
  HBV                           
  Positive                      54
  Negative                      12
  HBV DNA (copies/mL)           
  \> 2 × 10^3^                  30
  ≤ 2 × 10^3^                   36
  Cirrhosis                     
  Present                       50
  Absent                        16
  AFP (ng/mL)                   
  ≤ 100                         26
  \> 100                        40

AFP: Alpha-fetoprotein; HBV: Hepatitis B virus infection; BCLC: Barcelona Clinic Liver Cancer; ECOG PS: Eastern Cooperative Oncology Group performance status.

![Patient selection flowchart. mRECIST: Modified Response Evaluation Criteria in Solid Tumors; TACE: Transarterial chemoembolization; HAIC: Hepatic arterial infusion chemotherapy.](WJGO-12-663-g002){#F2}

Tumor response
--------------

A total of 66 participants were included in our study. The overall response rate (ORR) was 42.4% (28/37), including 9 (13.6%) participants with CR and 19 (28.8%) with PR. There were 30 (45.5%) participants with SD and 8 (12.1%) with PD. The disease control rate (CR, PR, or SD) was 87.9% (58/66) (Table [2](#T2){ref-type="table"}). One patient achieved CR based on the mRECIST criteria (Figure [3](#F3){ref-type="fig"}).

###### 

Tumor response (modified Response Evaluation Criteria for Solid Tumors)

  **Best tumor response**   **Participants, *n* (%)**
  ------------------------- ---------------------------
  DCR, CR + PR + SD         58 (87.9)
  ORR, CR + PR              28 (42.4)
  CR                        9 (13.6)
  PR                        19 (28.8)
  SD                        30 (45.5)
  PD                        8 (12.1)

All participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma. CR: Complete response; DCR: Disease control rate; PR: Partial response; SD: Stable disease; ORR: Objective response rate.

![Images from a 41-year-old woman with intermediate-stage hepatocellular carcinoma who underwent combination therapy with sorafenib with hepatic arterial infusion chemotherapy (folinic acid, 5-fluorouracil, and oxaliplatin) after transarterial chemoembolization. A and B: Preoperative computed tomography (CT) showed the lesion in the liver (arrow); C: Angiography *via* the proper hepatic artery revealed a tumor mass in the liver (arrow); D: Postoperative angiography revealed the scattered deposition of lipiodol within the lesions in the liver (arrow); E: After 1 year, angiography *via* the proper hepatic artery revealed scattered deposition of lipiodol within the lesions in the liver (arrow); F: After 1 year, CT revealed scattered deposition of lipiodol within the lesions in the liver, and the tumor lesions had no enhancement during the arterial phase (arrow).](WJGO-12-663-g003){#F3}

Survival and disease progression
--------------------------------

Follow-up was performed until May 2018. The median follow-up duration in this study was 22.0 mo (1-77 mo), during which time 45 participants died and 43 experienced PD. The median OS (mOS) was 21.8 mo (95%CI: 12.9-30.6 mo). The mOS of participants with BCLC stage B and BCLC stage C disease was 46.1 mo and 15.6 mo, respectively. The 1-, 2-, and 5-year mOS rates were 68.2%, 46.4%, and 25.6%, respectively. The mPFS was 13.1 mo (95%CI: 9.5-16.7 mo). The mPFS was 13.5 mo in the BCLC stage B participants and 9.4 mo in the BCLC stage C participants. The 6-mo, 12-mo-, and 24-mo PFS rates were 75.0%, 54.7%, and 30.0%, respectively (Figure [4](#F4){ref-type="fig"}). There were 49 (74.2%) patients who underwent MRI to evaluate the response, and 17 (25.8%) underwent CT to evaluate the response. There were no significant differences (*P* = 0.25 and *P* = 0.38) in the OS and PFS of patients who underwent MRI and CT.

![Kaplan-Meier curves of the progression-free survival and overall survival of patients with hepatocellular carcinoma who were treated with sorafenib combined with hepatic arterial infusion chemotherapy (folinic acid, 5-fluorouracil, and oxaliplatin) after transarterial chemoembolization and for Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma.](WJGO-12-663-g004){#F4}

Complications or AEs
--------------------

There were no treatment-related deaths in this study. The most common adverse reaction in this study was liver function damage (69.7%, 42/66), of which grade 3-4 liver function damage \[HAIC affected the aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels\] was observed in 12.2% (8/66) of the participants; liver function returned to normal after treatment. Three (4.5%) participants had grade 3-4 thrombocytopenia, and two (3.0%) had grade 3-4 neutropenia, which also returned to normal after treatment. Twenty-seven (40.9%) participants developed hand-foot skin reactions (HFSRs). One participant developed pneumonia, which resolved after treatment. No vascular complications were noted in any of the participants, and no cerebral hemorrhage was noted as a vascular complication (Table [3](#T3){ref-type="table"}).

###### 

Treatment-emergent and drug-related adverse events

  **Adverse event**                        **Participants, *n* (%)**             
  ---------------------------- ----------- --------------------------- --------- ---------
  Hematological                                                                  
  Decreased platelet count     14 (21.2)   8 (12.1)                    3 (4.5)   0 (0)
  Decreased neutrophil count   15 (22.7)   11 (16.7)                   2 (3.0)   0 (0)
  Non-hematological                                                              
  Elevated alanine             30 (45.5)   8 (12.1)                    4 (6.1)   4 (6.1)
  Elevated serum bilirubin     20 (30.3)   26 (39.4)                   5 (7.6)   0 (0)
  Nausea and vomiting          32 (48.5)   8 (12.1)                    0 (0)     0 (0)
  Pain                         29 (43.9)   11 (16.7)                   0 (0)     0 (0)
  Fever                        4 (6.1)     2 (3.0)                     0 (0)     0 (0)
  Diarrhea                     10 (15.2)   6 (9.1)                     0 (0)     0 (0)
  Hand-foot skin reaction      7 (10.6)    16 (24.2)                   4 (6.1)   0 (0)
  Neurotoxicity                18 (27.3)   7 (10.6)                    0 (0)     0 (0)

Data are the number of patients, with percentages in parentheses; all participants were treated with hepatic arterial infusion chemotherapy (oxaliplatin, 5-fluorouracil, and folinic acid) after transarterial chemoembolization combined with sorafenib for intermediate and advanced hepatocellular carcinoma.

DISCUSSION
==========

This prospective study achieved the prespecified primary endpoint of a 12-mo PFS rate exceeding 54.7%. The combination of TACE-HAIC and sorafenib is considered to be safe. Most guidelines for HCC management recommend TACE as a first-line treatment for patients with unresectable HCC\[[@B38],[@B39]\].

A previous study\[[@B40]\] combined local treatment methods and showed that combination therapy consisting of HAIC (EPF \[etoposide, cisplatin, and 5-FU\] and EAP \[etoposide, adriamycin or epi-adriamycin, and cisplatin\]) and TACE was better than transarterial embolization alone for unresectable advanced HCC. Several studies\[[@B41],[@B42]\] have explored HAIC in advanced HCC with PVTT and reported survival benefits. However, there are no reports on the combination of sorafenib and TACE-HAIC for BCLC stage B/C HCC. In the studies conducted at our center\[[@B21],[@B22]\], the mPFS and ORR of combined TACE with HAIC were superior to those of TACE alone.

We considered that there is a rationale for combining TACE with HAIC. First, the flow of the tumor-feeding artery slows down after TACE, and chemotherapy can be maintained at high blood concentrations for an extended period in the tumor tissue. Second, TACE causes tumor tissue ischemia, hypoxia, and tumor cell transmembrane ion pump failure, preventing the chemotherapy agent from being pumped out of the cell\[[@B43]\]. Finally, HCC mostly consists of microfocal cancer lesions after TACE, and HAIC can clear these lesions. TACE inevitably results in hypoxic insult to tumors and enhanced expression of circulating or tissue angiogenic factors (vascular endothelial growth factor) after TACE, which could be associated with unfavorable outcomes\[[@B44]\]. Treatment with a combination of an anti-angiogenic agent (sorafenib) and TACE may provide complementary inhibition of neovascularization and tumor growth. Phase III trials\[[@B45],[@B46]\] have revealed the potential superiority of combined TACE plus sorafenib over TACE alone. In our study, we selected oxaliplatin-based HAIC therapy because some studies have proven that HAIC (FOLFOX) is safe and effective for HCC\[[@B8],[@B35]-[@B37]\]. Furthermore, sorafenib and FOLFOX agents exert synergistic antitumor effects\[[@B47]\].

In this prospective cohort study, the mOS and mPFS were 21.8 mo and 13.1 mo, respectively. Compared with other studies, the mPFS in our study was better than that (7.2-7.9 mo) of TACE combined with sorafenib reported in two III trials\[[@B45],[@B46]\]. The mOS and mPFS in our study were superior to those of sorafenib plus HAIC reported in a randomized phase III trial (21.8 mo *vs* 13.37 mo; 13.1 mo *vs* 7.13 mo)\[[@B36]\]. In this study, TACE combined with HAIC may have prolonged the mPFS by clearing residual tumor lesions. The phase III study enrolled different participants. In addition, in our study, we enrolled 37 (56.1%) participants with BCLC stage C disease, and the mOS and mPFS of these patients were 15.6 mo and 9.4 mo, respectively. We enrolled 16 patients with extrahepatic metastases. Most patients with HCC die from the progression of intrahepatic lesions; thus, it is important to control intrahepatic lesions. Sorafenib is the first-line drug for advanced HCC, which includes HCC with PVTT and/or extrahepatic metastases. Systemic treatment with sorafenib combined with the local treatment of TACE-HAIC may prolong survival. We enrolled 23 participants with portal vein invasion, and among these patients, the mOS was 13.6 mo, and the mPFS was 7.7 mo. The phase III trial (sorafenib-HAIC group *vs* sorafenib group)\[[@B36]\] enrolled patients with HCC with portal vein invasion, and the reported mPFS was 7.03 mo. However, these studies are not suitable for further in-depth comparison due to the heterogeneity of the trial participants.

The combination of TACE-HAIC and sorafenib is considered to be safe, and no treatment-related deaths were observed in this study. In addition, the rate of grade 3-4 toxicities was similar to that reported in a previous study, which consisted of increased AST levels (12.2% *vs* 31.4%), thrombocytopenia (4.5% *vs* 12.9%-14.3%), and neutropenia (3.0% *vs* 8.6%-9.7%). A total of 40.9% (27/66) of participants developed HFSRs, similar to that reported in a previous study\[[@B35],[@B36],[@B45],[@B48]\]. Furthermore, the combination of TACE-HAIC and sorafenib was well tolerated, suggesting that this combination therapy does not increase the incidence of adverse reactions compared with HAIC alone. In our study, we found that HAIC affected ALT and AST, but these levels normalized soon after treatment. The rate of grade 3-4 AEs was less than that reported in a previous study (TACE-2), and the reasons may be as follows: First, the dosages of the drugs were reduced (oxaliplatin, 60-75 mg/m^2^; 5-FU, 1.0-1.5g/m^2^); however, the dosages of intravenous medication were 130 mg/m^2^ (oxaliplatin) and 2.4 g/m^2^ (5-FU), and the toxicity was tolerable. Second, the cTACE protocol used in the present study is different from the TACE protocol used in the TACE-2 study. By preserving the blood flow of the main artery to perform HAIC, cTACE results in an incomplete embolism, and chemotherapy is then infused into the tumors. The incomplete embolism can reduce AEs. It is important to adjust the drug dosage according to AEs. If a participant exhibited grade 3-4 myelosuppression, we decreased the dose of oxaliplatin and 5-FU or sorafenib.

For intermediate-stage HCC, TACE is the current standard of treatment, and TACE with drug-eluting beads provided a longer time to progression but did not improve survival in comparison with cTACE. For HCC with PVTT or a large nodule size, transarterial radioembolization (TARE) can prolong OS compared with sorafenib or TACE. However, patients cannot access yttrium 90 in Mainland China; thus, for patients with advanced HCC (segmental portal vein thrombosis, large nodule size, and Child-Pugh A disease) who do not have access to or are intolerant to sorafenib or TARE, TACE might be an alternative treatment\[[@B49]-[@B52]\].

In this study, the prognosis of advanced HCC was significantly worse than that of intermediate HCC. There are some other treatments for advanced HCC: Lenvatinib as a first-line drug was approved in the REFLECT trial\[[@B53]\], and the median OS was 13.6 mo. Regorafenib and cabozantinib are the second-line drugs for advanced HCC and were approved in the RESORCE and CELESTIAL trials\[[@B54],[@B55]\], and the median OS was 10.2-10.6 mo. Nivolumab and pembrolizumab were approved in two phase II clinical trials, and the ORR was 15%-15.6%\[[@B56],[@B57]\], but OS was not assessed. Radiotherapy is a common treatment method for unresectable HCC; in a meta-analysis\[[@B58]\], radiotherapy plus TACE was evaluated for unresectable HCC, and the OS was longer than that with TACE alone (22.7 mo *vs* 13.5 mo, *P* \< 0.001, respectively).

There were some limitations in our study. First, because this was a single-arm study, it cannot produce powerful results because the sample size of our single-center trial may not have been large enough; thus, biases existed in our results. Therefore, prospective randomized controlled trials with larger sample sizes are required to further verify these results. Second, we used the mRECIST to evaluate the effect. However, contrast-enhanced CT has a slight disadvantage in assessing subtle areas of contrast enhancement within a tumor that has retained large amounts of lipiodol. To reduce the bias in our study, radiologists with over 10 years of experience with combined CT and MRI assessed the effects, and we tried to keep the imaging examination (CT or MRI) consistent before and after treatment to increase accuracy. In addition, 49 (74.2%) patients underwent MRI to evaluate the tumor response, and 17 (25.8%) underwent CT to evaluate the tumor response; there were no significant differences in the OS (*P* = 0.25) and PFS (*P* = 0.38) of patients who underwent MRI and CT.

In conclusion, in this phase II study, TACE-HAIC therapy combined with sorafenib for participants with BCLC stage B/C HCC is safe and effective. However, prospective randomized controlled trials are needed to confirm the effect of TACE-HAIC combined with sorafenib.

ARTICLE HIGHLIGHTS
==================

Research background
-------------------

Sorafenib has been proven effective for advanced hepatocellular carcinoma (HCC), transarterial chemoembolization (TACE) is the standard therapy for intermediate HCC, and hepatic arterial infusion chemotherapy (HAIC) is a safe and effective treatment for advanced HCC. Herein, we aimed to identify the safety and efficacy of combining sorafenib with HAIC after TACE for intermediate and advanced HCC.

Research motivation
-------------------

Although there are many treatment methods for HCC, the therapeutic effect is very limited and does not significantly prolong patient survival. Safer and more effective protocols need to be developed to improve therapeutic effects.

Research objectives
-------------------

To provide an effective combined treatment protocol based on previous studies.

Research methods
----------------

All patients initially received the standard 400 mg dose of sorafenib twice daily before TACE-HAIC. Participants at our institute with intermediate and advanced HCC underwent routine TACE. Then, the catheter used for embolization was kept in place in the feeding artery of the tumor, and oxaliplatin was intra-arterially administered for 6 h, followed by 5-fluorouracil (5-FU) for 18 h, and folinic acid was intravenously administered for 2 h.

Research results
----------------

The overall response rate was 42.4%. The disease control rate was 87.9%. The grade 3-4 toxicities consisted of thrombocytopenia (4.5%), neutropenia (3.0%), and elevated aspartate aminotransferase (12.2%). Hand-foot skin reaction was also observed (40.9%). The median progression-free survival was 13.1 mo, (13.5 mo in participants with Barcelona Clinic Liver Cancer (BCLC) stage B disease and 9.4 mo in participants with BCLC stage C disease). The 6-mo, 12-mo, and 24-mo PFS rates were 75.0%, 54.7%, and 30.0%, respectively. The median overall survival was 21.8 mo.

Research conclusions
--------------------

Sorafenib combined with HAIC (folinic acid, 5-FU, and oxaliplatin) after TACE may be a feasible treatment choice for intermediate and advanced HCC based on patient tolerance and survival.

Research perspectives
---------------------

The combination of sorafenib and TACE-HAIC has been shown to be effective with limited complications. Prospective randomized controlled trials are needed to confirm the effect of this combination therapy.
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